The technology has been licensed by the Medical College of Wisconsin (Milwaukee, USA) to GE Healthcare (Chalfont St. Giles, UK). Under the license, GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.
The probes bind to dead and dying cells making them useful for detecting acute cell injury and cell death. When the active component of this molecule is attached to a radioactive tracer, it can be used in nuclear medicine imaging techniques, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), to generate three-dimensional images of where this cell death is occurring.
"We are pleased to be working with GE on this technology,” said Dennis Devitt, the director of marketing and licensing for the Office of Technology Development (OTD), the technology transfer arm of the Medical College. "Working with the market leader in medical imaging allows this technology to be quickly moved from the research laboratory into patient care,” Dr. Devitt said.
According to Dr. Zhao, "Imaging agent discovery and development is an important aspect in molecular and medical imaging research. The process is critical for the improvement of existing imaging technologies and for early detection of acute cell death, cancerous tissue growth, and major vessel diseases.”
The ability to image dead and dying cells can have major clinical benefits, according to Dr. Zhao. For example, it could allow oncologists to rapidly monitor tumor response to a specific therapy. Another potential application is for rapid diagnosis of myocardial infarction. Often patients come into the emergency room (ER) complaining of chest pain and need to have an expensive overnight hospital stay so they can be monitored while their lab results are being processed. This compound could allow clinicians to noninvasively image the heart and determine within a few hours if the patient actually had a heart attack or something else.
Joseph Hill, vice president for technology development, added that Dr. Zhao's research was supported by a Proof-of-Concept grant administered by the College's OTD. They have filed several patent applications on the technology. The OTD patents intellectual property generated by faculty and staff at the Medical College and licenses it in line with its mission to commercialize as many inventions as possible to help patients.
Related Links:
Medical College of Wisconsin
GE Healthcare
